Escape Meridian

MIT Technology Review · Nov 25, 2024

MIT Technology Review’s The Download on tariffs and proposed Google remedies

Markdown · JSON · Original source

MIT Technology Review’s November 25, 2024, edition of The Download highlights possible costs from Donald Trump’s tariff plans and the US Department of Justice’s proposed remedies in its antitrust case against Google. James Temple writes that the president-elect’s “America First” plan threatens to raise costs and slow US cleantech projects; he says materials for batteries, electric vehicles, and energy infrastructure could become more expensive for companies and consumers. Mat Honan describes the DOJ’s proposals as profound and says they could be catastrophic to Google’s business if enacted. Google was expected to submit its own proposals, after which Judge Amit Mehta would decide which remedies, if any, to enact; the newsletter asks what role the incoming Trump administration will play. The edition also revisits Jessica Hamzelou’s argument that easier access to experimental medicines can expose people to treatments that may not help and could harm them, while anecdotes may outweigh evidence in drug approval decisions. The newsletter’s accounts describe possible consequences, not outcomes: the tariff effects, the court’s decision, and the administration’s role remain unknown.

Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.

MIT Technology ReviewArticle · technologyreview.comOpen original source

Original source

MIT Technology Review · Article

Source details

Original source date: Nov 25, 2024 (2024-11-25T13:10:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-16T09:53:31.862Z. First observed: 2026-10-31T16:08:14.476Z. Retrieved: 2026-10-31T16:09:55.136Z.

Referenced by

Recorded citations in public readings. A reference alone does not establish agreement or influence.

No public references recorded here yet.

Reference data (JSON)

Limits

Text as retrieved on October 31, 2026; originally published November 25, 2024. The newsletter summarizes and links to fuller stories; the retrieved text does not provide the underlying reporting or further detail on the proposed Google remedies.

Open question

What remedies will Judge Amit Mehta choose, if any, and what role will the incoming Trump administration play?

Source-stated

James Temple writes that Trump’s tariff plans could raise costs and slow US cleantech projects.

President-elect Donald Trump’s “America First” plan to enact huge tariffs on imported goods threatens to jack up the cost and slow down the development of US cleantech projects.

Source-stated

James Temple says tariffs could increase what US companies and consumers pay for energy-related materials and products.

These plans could easily add billions of dollars to the prices that US companies—and therefore consumers—pay for batteries and electric vehicles

Source-stated

Mat Honan describes the DOJ’s proposed remedies as profound and potentially catastrophic to Google’s business if enacted.

the remedies it did suggest are profound and, if enacted, could be catastrophic to its business.

Source-stated

The newsletter says Judge Amit Mehta will decide which, if any, proposed remedies to enact, and asks what role the incoming Trump administration will play.

Judge Amit Mehta, who has been presiding over the case, will have to decide which, if any, of these remedies to enact. So what is the DOJ proposing, and what role will the incoming Trump administration play?

Source-stated

Jessica Hamzelou argues that access to experimental therapies raises questions about who should receive them and who should decide.

Who should have access to experimental therapies? And who should get to decide?

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Editorial provenance

Version 1. Publication ID: 267f806e-ef34-a68b-cd4f-b2aa65c54fd4.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: passed by anthropic/claude-opus-5.5 on 2026-11-16T09:48:56.275Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model, second_opinion_categorical.

Observation: 714b86f99c633d7758caba0b5267f23fad8502909feaf734181fcefc981bb234. Source text hash: f8eef81c4e7fcd42512f5a1834120f1c99b6e35abf13d6f80ee47b5b7194f757.

Revision and source-check history

Version 1 · 2026-11-16T09:53:31.862Z

MIT Technology Review’s The Download on tariffs and proposed Google remedies

MIT Technology Review’s November 25, 2024, edition of The Download highlights possible costs from Donald Trump’s tariff plans and the US Department of Justice’s proposed remedies in its antitrust case against Google. James Temple writes that the president-elect’s “America First” plan threatens to raise costs and slow US cleantech projects; he says materials for batteries, electric vehicles, and energy infrastructure could become more expensive for companies and consumers. Mat Honan describes the DOJ’s proposals as profound and says they could be catastrophic to Google’s business if enacted. Google was expected to submit its own proposals, after which Judge Amit Mehta would decide which remedies, if any, to enact; the newsletter asks what role the incoming Trump administration will play. The edition also revisits Jessica Hamzelou’s argument that easier access to experimental medicines can expose people to treatments that may not help and could harm them, while anecdotes may outweigh evidence in drug approval decisions. The newsletter’s accounts describe possible consequences, not outcomes: the tariff effects, the court’s decision, and the administration’s role remain unknown.

Original source

MIT Technology Review · Article

Source details

Original source date: Nov 25, 2024 (2024-11-25T13:10:00Z).

Date basis: Date from the publisher’s own records, through its API.

Added to Escape Meridian: 2026-11-16T09:53:31.862Z. First observed: 2026-10-31T16:08:14.476Z. Retrieved: 2026-10-31T16:09:55.136Z.

Limits

Text as retrieved on October 31, 2026; originally published November 25, 2024. The newsletter summarizes and links to fuller stories; the retrieved text does not provide the underlying reporting or further detail on the proposed Google remedies.

Open question

What remedies will Judge Amit Mehta choose, if any, and what role will the incoming Trump administration play?

Source-stated

James Temple writes that Trump’s tariff plans could raise costs and slow US cleantech projects.

President-elect Donald Trump’s “America First” plan to enact huge tariffs on imported goods threatens to jack up the cost and slow down the development of US cleantech projects.

Source-stated

James Temple says tariffs could increase what US companies and consumers pay for energy-related materials and products.

These plans could easily add billions of dollars to the prices that US companies—and therefore consumers—pay for batteries and electric vehicles

Source-stated

Mat Honan describes the DOJ’s proposed remedies as profound and potentially catastrophic to Google’s business if enacted.

the remedies it did suggest are profound and, if enacted, could be catastrophic to its business.

Source-stated

The newsletter says Judge Amit Mehta will decide which, if any, proposed remedies to enact, and asks what role the incoming Trump administration will play.

Judge Amit Mehta, who has been presiding over the case, will have to decide which, if any, of these remedies to enact. So what is the DOJ proposing, and what role will the incoming Trump administration play?

Source-stated

Jessica Hamzelou argues that access to experimental therapies raises questions about who should receive them and who should decide.

Who should have access to experimental therapies? And who should get to decide?

Source and contributor context

MIT Technology Review · Publisher

The publisher is identified here. No individual author has been inferred.

Source media

Media retrieval status: unchecked.

Terms and references

Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.

Editorial provenance

Version 1. Publication ID: 267f806e-ef34-a68b-cd4f-b2aa65c54fd4.

Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.

Source check: passed by anthropic/claude-opus-5.5 on 2026-11-16T09:48:56.275Z. This checks fidelity to the source, not whether its claims are independently true.

Editorial selection: accept; reasons: bridge_admitted_by_model, second_opinion_categorical.

Observation: 714b86f99c633d7758caba0b5267f23fad8502909feaf734181fcefc981bb234. Source text hash: f8eef81c4e7fcd42512f5a1834120f1c99b6e35abf13d6f80ee47b5b7194f757.

passed · 2026-11-16T09:48:56.275Z · anthropic/claude-opus-5.5

Publication: 267f806e-ef34-a68b-cd4f-b2aa65c54fd4

attribution — pass: This is one newsletter issue of MIT Technology Review's The Download, with commentary in the editors' own words, so it is one piece and not a listing. The reading credits James Temple for the tariff item, Mat Honan for the Google item and Jessica Hamzelou for the experimental-treatments item, matching the bylines in the text.

This is today's edition of The Download, our weekday newsletter

summary — pass: The reading leads with the two main items, names the actors (Trump, DOJ, Google, Judge Amit Mehta) and keeps each writer's force, including 'profound' and 'catastrophic'. Terms such as remedies and antitrust are used in plain context that a general reader can follow. The question reflects the open issue the source itself raises. Describing the 2023 big story as 'revisits' is accurate.

So what is the DOJ proposing, and what role will the incoming Trump administration play?

date — pass: The reading's November 25, 2024 date matches the UTC day of originalPublished (2024-11-25T13:10Z). Forecasts about tariffs and the court are kept conditional and stated as unknown, with no hindsight framing. The Deep Dive links that mention later events (e.g., OpenAI math findings) are probably later page additions; the reading does not use them. The kind is publisher-page, so no archive disclosure is required.

support — pass: Each claim matches its quoted excerpt. The summary's paraphrase of Hamzelou ('anecdotes may outweigh evidence') softens the source's 'appear to be overpowering' faithfully. The reading adds no stakeholder benefits or costs beyond what the source states.

Anecdotes appear to be overpowering evidence in decisions on drug approval.

media — pass: No media was selected and no verified candidates were supplied, so nothing is misidentified.

Challenge or correct this reading

Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.